Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Heron Therapeutics Inc (HRTX) vs iShares Global Tech ETF (IXN) Price & Performance

Heron Therapeutics IncTrade
iShares Global Tech ETFTrade

Price performance (Past 24H)

Key statistics

Heron Therapeutics Inc vs iShares Global Tech ETF — how do they compare? Heron Therapeutics Inc trades at $0.47 (market cap $91.46M), while iShares Global Tech ETF trades at $134. The key difference: iShares Global Tech ETF is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.

HRTXIXN
Market Cap
$91.46M
Sector
HealthSector/Thematic
52-Week High
$1.96$149.74
52-Week Low
$0.39$94.04
Enterprise Value
$189.36M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Heron Therapeutics Inc

HRTX trades at $0.4804, up 2.06% today, with a bullish technical signal despite mixed earnings. The stock shows a low price-to-sales ratio of 0.51 but negative profitability, with a net income margin of -20.53% in 2026. Recent Q1 2026 earnings missed expectations, though management reaffirmed full-year guidance. Analyst consensus is strongly bullish with 94.7% buy ratings.

Outlook remains speculative given persistent losses and cash burn, but potential upside exists if operational improvements materialize. Key risks include patent litigation outcomes and reliance on revenue growth to achieve profitability. Investors should weigh high analyst optimism against fundamental challenges.

iShares Global Tech ETF

IXN trades at $132.95 with minimal daily movement (+0.25%). Technical indicators show a neutral to bearish bias with mixed signals from moving averages and oscillators. The stock faces resistance near $139-$141 while finding support around $133-$136. Recent analysis highlights strong technology sector exposure but cautions about elevated valuations and concentration risks in the portfolio.

The outlook remains cautious as current price levels reflect significant optimism about AI-driven growth. Investment opportunity lies in continued technology sector leadership, while risks include valuation concerns and sector concentration. Analyst sentiment leans neutral with expectations for clearer earnings growth catalysts before more bullish positioning.

Returns comparison

Trailing returns across standard periods

About Heron Therapeutics Inc

Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.

Read more on HRTX

About iShares Global Tech ETF

IXN provides exposure to global electronics, software, and hardware companies. It tracks the S&P Global 1200 Information Technology Index, covering tech leaders across both developed and emerging markets.

Read more on IXN